MannKind | MNKD - Assets


MannKind reported $732.3M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Adma Biologics USD 684.21M 19.03M Jun/2026
BioCryst Pharmaceuticals USD 557.85M 92.8M Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Halozyme Therapeutics USD 2.58B 95.31M Jun/2026
Insmed USD 2.1B 26.7M Jun/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
MacroGenics USD 345.41M 127.54M Jun/2026
MannKind USD 732.3M 12.1M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Novavax USD 955.58M 87.59M Jun/2026
Novo Nordisk DKK 90.92B 468.3B Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026
Xencor USD 724.96M 11.89M Jun/2026